Eli Lilly, JPM, Novo Nordisk, Bain

Sign up for the biotech newsletter to stay on top of the latest science and politics driving the biotech industry. The newsletter includes previews of biotech conferences, updates on obesity drug development, and IPO filings. The need-to-know includes warnings from Eli Lilly on the use of its weight loss drugs, a judge’s recommendation to dismiss a defamation lawsuit, and updates on the J.P. Morgan Healthcare Conference. Additionally, Moonwalk Therapeutics is working on a gentler approach to genome editing, Novo Nordisk is developing weight-loss drugs using genome editing, and CG Oncology has filed for an IPO. These developments are shaping the future of the biotech industry.

Source link

error: Content is protected !!